SEC Investigates Par Pharmaceutical

Law360, New York (July 25, 2006, 12:00 AM EDT) -- The U.S. Securities and Exchange Commission is investigating Par Pharmaceutical Companies Inc. following the company’s July 5 announcement that it will restate its financial results for the fiscal years 2004 and 2005, and the first quarter of 2006.

The revelation of the SEC inquiry came on the heels of at least two shareholder suits against Par.

In a July 24 filing with the SEC, Par reported that it had received a letter—dated July 7—from the SEC saying it had launched an informal investigation related to Par’s...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.